腺苷再攝取抑制劑
外觀
![]() | 此條目可參照英語維基百科相應條目來擴充。 |
![](http://upload.wikimedia.org/wikipedia/commons/thumb/e/e8/Adenosin.svg/200px-Adenosin.svg.png)
腺苷再攝取抑制劑(Adenosine reuptake inhibitor,縮寫為AdoRI)是一類藥物,它通過阻斷一個或多個平衡核苷轉運蛋白(ENTs)的作用,作為嘌呤核苷和神經遞質腺苷的再攝取抑制劑。[1][2][3]這繼而導致腺苷的細胞外濃度增加,因此腺苷能神經傳遞增加。
參考資料
[編輯]- ^ SenGupta DJ, Unadkat JD. Glycine 154 of the equilibrative nucleoside transporter, hENT1, is important for nucleoside transport and for conferring sensitivity to the inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep. Biochem Pharmacol. 2004, 67 (3): 453–458. PMID 15037197. doi:10.1016/j.bcp.2003.09.018.
- ^ Endres CJ, Sengupta DJ, Unadkat JD. Mutation of leucine-92 selectively reduces the apparent affinity of inosine, guanosine, NBMPR [S6-(4-nitrobenzyl)-mercaptopurine riboside] and dilazep for the human equilibrative nucleoside transporter, hENT1. Biochem J. 2004, 380 (1): 131–137. PMC 1224139
. PMID 14759222. doi:10.1042/BJ20031880.
- ^ Chaudary N, Naydenova Z, Shuralyova I, Coe IR. The adenosine transporter, mENT1, is a target for adenosine receptor signaling and protein kinase Cepsilon in hypoxic and pharmacological preconditioning in the mouse cardiomyocyte cell line, HL-1. J Pharmacol Exp Ther. 2004, 310 (3): 1190–1198. PMID 15131243. doi:10.1124/jpet.104.067157.
|